Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition

Video

This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer.

In this video, Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012 trial, which studied abiraterone and prednisone with or without the PARP inhibitor veliparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

Hussain reports that ETS fusion–positive tumors did not predict response to treatment, but also that the design of the trial allowed investigators to discover a surprise finding among patients with DNA repair gene–deficient tumors.

The study results were presented (abstract 5001) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content